Administration of an Oral PDE5 Inhibitor, Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma.

Trial Profile

Administration of an Oral PDE5 Inhibitor, Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Tadalafil (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 Planned End Date changed from 1 Feb 2015 to 1 Jul 2017.
    • 17 Apr 2013 Planned End Date changed from 1 Feb 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
    • 15 Nov 2012 Planned end date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top